Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)
Johnson & Johnson (JNJ) posted Income from Continuing Operations of 5534000000.0 for Q2 2026, up 5.71% sequentially from 5235000000.0 in Q1 2026, and little changed YoY from 5537000000.0 in Q2 2025.
Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Income from Continuing Operations for 18 years, with the latest figure at 5534000000.0 in Q2 2026.
- Quarterly Income from Continuing Operations changed 0.05% year-over-year to 5534000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21037000000.0 (down 7.17% YoY) and the FY2025 annual result came in at 26804000000.0, up 90.56% from the prior year.
- Income from Continuing Operations advanced to 5534000000.0 in Q2 2026 per JNJ's latest filing, from 5235000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 10999000000.0 in Q1 2025 and troughed at 491000000.0 in Q2 2023.
- A 5-year average of 4474000000.0 and a median of 4400000000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 110.94% in 2023, then jumped 762.93% in 2024.
- Over 5 years, Income from Continuing Operations stood at 4310000000.0 in 2022, then slipped by 4.13% to 4132000000.0 in 2023, then dropped by 16.97% to 3431000000.0 in 2024, then soared by 49.11% to 5116000000.0 in 2025, then gained by 8.17% to 5534000000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5534000000.0, 5235000000.0, and 5116000000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 5.53 Bn |
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.13 Bn |
| Oct 1, 2023 | 4.31 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 2.65 Bn |
| Oct 2, 2022 | 4.31 Bn |
| Jul 3, 2022 | 4.12 Bn |
| Apr 3, 2022 | 4.49 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |